Abstract 576P
Background
Tumor immune contexture plays a crucial role in the outcome of cancer patients. The aim of this study was to evaluate the prognostic value of the modified diagnostic biopsy-adapted immunoscore (mISb) for patients with locally advanced rectal cancer (LARC).
Methods
We included 181 LARC patients from a single sub-center of a prospective study (NCT02533271), with 151 (83.4%) receiving surgical treatment and 30 (16.6%) following a watch-and-wait (W&W) strategy. Tumor biopsy tissues were stained using dual immunohistochemistry for CD8+ and CD3+ T cell densities, and the CD8/CD3 ratio was calculated. mISb was developed using mean percentile values of CD8+ T cell density and CD8/CD3 ratio, and patients were classified into low (0%-25%), intermediate (>25%-70%), and high (>70%-100%) mISb groups. Spearman correlation analysis was performed. Kaplan-Meier survival analysis, multivariate Cox regression models were used to assess the prognostic value of mISb for disease-free survival (DFS), and the role of mISb in the W&W strategy was further investigated.
Results
A strong correlation was found between CD8+ and CD3+ T cell densities (R=0.86, P<0.001), and a weaker correlation with the CD8/CD3 ratio (R=0.45). In the low, intermediate, and high mISb groups, there were 35 (23.2%), 84 (55.6%), and 32 (21.2%) patients, respectively. The respective 3-year DFS rates for these groups were 59.0%, 69.5%, and 80.1% (P=0.01). Multivariate analysis in surgically treated patients revealed mISb as an independent prognostic factor for DFS (intermediate vs. high: HR=2.38, 95% CI: 0.92-6.16, P=0.08; low vs. high: HR=3.69, 95% CI: 1.35-10.07, P=0.01). Among W&W patients, 6 (37.5%) in the mISb≤50% group experienced local-region or distant metastases, while only 1 (7.1%) in the mISb>50% group had local-region recurrence.
Conclusions
mISb, as a potentially valuable prognostic indicator, demonstrates significant importance in assessing the prognosis of LARC patients. Future research is needed to further investigate the clinical application of mISb in rectal cancer prognosis, particularly in the context of the W&W strategy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10